You are here:     > About Glenmark | Business at a Glance

Business at a Glance  

Highlights
Amongst
80
top pharma companies in the world*
 
8th
rank among pharma companies in Asia **
 
10th
rank among pharma companies based out of emerging
markets ***
 
Fastest
growing among top 20 pharmaceutical companies in India ****
 
11
finished dosage plants in four countries
 
5
API plants in India for commercial and captive requirements
 
01
biologics manufacturing site in Switzerland
 
07
innovative molecules in advanced clinical and pre-clinical stages of development
Based on closing pricing on NSE as on 31 May 2016
* SCRIP Rankings 2016     ** Excludes Japan     *** Includes countries like Brazil, Russia, India, China and South Africa     **** In terms of retail formulation sales (Source: IMS)

Our Business is Primarily Structured into Drug Discovery & Development, Branded and Generic Formulations, and Active Pharmaceutical Ingredients (APIs). Our fast growing formulations business services the requirements of developed markets such as the United States and Europe. We have also built a strong presence in the branded generic formulations segment across emerging economies like India, Russia and Brazil. With a presence across the value chain, we market APIs to regulated and semi-regulated markets. Our Drug Discovery has 2 New Chemical Entities (NCEs) and 5 New Biological Entities (NBEs) which are in various stages of pre-clinical and clinical development. It is this global footprint that helps us in our mission of enriching lives worldwide.

  • Drug Discovery

    We believe innovation is the only way to build a truly global organization that delivers outstanding results. In line with this belief, our ground-breaking drug discovery efforts are focused on the therapeutic areas of inflammation, pain and oncology.

  • Generic Formulations

    Our Generic Formulations business primarily comprises of the U.S and Western Europe. Our U.S business is the largest market for us with more than 100 products authorized to distribute and approximately 60 pending approvals with the U.S. FDA. We also have a strong presence in the UK and are the fastest growing generics company in Germany.

  • Branded Formulations

    In pursuit of the mission of enriching lives, our Branded Formulations business has grown from strength-to-strength in the emerging markets globally, focused on the therapeutic areas of dermatology, anti-infective, respiratory, cardiology, diabetes, gynecology, oncology and the central nervous system.

  • Active Pharmaceutical Ingredients

    Our API division partners with leading global generic companies, supporting through advanced process chemistry skills and innovative intellectual property. We are a market leader for many API products in semiregulated markets and regulated markets.